Subscribe

0

  • Sign in with Email

By clicking the button, I accept the Terms of Use of the service and its Privacy Policy, as well as consent to the processing of personal data.

Don’t have an account? Signup

  • Bookmarks
  • My Profile
  • Log Out
  • NEWS
  • POLICIES
  • MSME OPPORTUNITIES
  • BANKING & FINANCE
  • TECHNOLOGY FOR SMES
  • SECTORS
  • GLOBAL
  • Investment
  • LEGAL
  • KNOWLEDGE QUEST
  • Future Ready Forum 2025
  • Ek Nayi Udaan
  • Future Ready Summit 2024
  • ADVERTISE WITH US
ad_close_btn
  • News
  • Policies
  • Banking & Finance
  • MSME Opportunities
  • Web Stories
  • InFocus
  • Technology For SMEs
  • Sectors
  • Global
  • Fashion

Powered by :

You have successfully subscribed the newsletter.
InFocus Corporate

Hester Biosciences Ltd Reported PAT of Rs. 13.29 Crore in Q3FY21, Growth of 72% Y-o-Y

Poultry Healthcare division and Animal healthcare division post 32% and 4% growth; Company is set to launch a new range of Herbal Health products in this quarter.

author-image
SMEStreet Edit Desk
31 Jan 2021 09:08 IST

Follow Us

New Update
Mr. Rajiv Gandhi, CEO & MD, Hester Biosciences Ltd

Leading animal healthcare company, Hester Biosciences Ltd reported net profit of Rs. 13.29 crore for the Q3FY21 ended December 2020 as against net profit of Rs. 7.73 crore in the corresponding period last year – growth of 72%. Net sales for the Q3FY21 was reported at Rs. 52.82 crore, growth of 22% as compared to net sales of Rs. 43.39 crore in the corresponding period last year. EPS for Q3FY was reported at Rs. 15.62 per share. Company is able to maintain healthy margins; EBITDA Margin was reported at 38.97% while Net Profit margin further improved to 25.16% in Q3FY21. The Board has authorised the management to explore appropriate financing alternatives for the expansion activities for an aggregate outlay of INR 200 Crore.

 

Financial Highlights

                                                                                                                        INR in Crore

Particulars Q3 9M
FY21 FY20 Growth FY21 FY20 Growth
Net Sales 52.82 43.39 22% 145.32 127.99 14%
Net Profit 13.29 7.73 72% 31.04 26.22 18%
EPS (In INR) 15.62 9.09 72% 36.49 30.82 18%

Performance – Division wise

                                                                                                                                       INR Crore

Particulars Q3 9M
FY21 FY20 Growth FY21 FY20 Growth
Poultry Healthcare 39.61 30.02 32% 103.78 90.46 15%
Animal Healthcare 9.90 9.48 4% 30.83 25.88 19%
Other 3.31 3.89 (15%) 10.71 11.65 (8%)
TOTAL 52.82 43.39 22% 145.32 127.99 14%

Poultry Healthcare division reported sales growth of 32% while Animal healthcare division reported sales growth of 4% Y-o-Y in Q3FY21. Vaccine division (Poultry and animal divisions) reported growth of 20% in Q3FY21 and 12% in 9MFY21 as compared to the corresponding period last year. Domestic sales have registered a growth of 43% in Q3FY21 and 20% in 9MFY21 while the export sales have reduced by 51% in Q3FY21 and 5% in 9MFY21. While export orders have continued to pour in, the higher demand within India compelled us to divert the production for domestic sales.

Going forward, Hester is set to launch a new range of Herbal Health products in this quarter. Hester is also evaluating expansion opportunities in manufacturing and distribution of Animal Health Products and Biologicals, worldwide. In view of the various vaccine opportunities within India, including those of Brucella and LSD vaccines, till our expansion activities go on-stream, temporarily, Hester will focus on the Indian market. Exports will be mainly of health products. Our developmental activities are ongoing for the human Covid-19 vaccine with IIT Guwahati.

The outcome of the tender for Brucella vaccine under the National Animal Disease Control Program of the Government of India is awaited. Sales through this tender are expected to commence from March 2021. There has been no impact on our sales due to the current Bird Flu situation in India.

Rajiv Gandhi Hester Biosciences
Subscribe to our Newsletter! Be the first to get exclusive offers and the latest news
logo

Related Articles
Read the Next Article
Latest Stories
Subscribe to our Newsletter! Be the first to get exclusive offers and the latest news

Latest Stories
Latest Stories
    Powered by


    Subscribe to our Newsletter!




    Powered by
    Select Language
    English

    Share this article

    If you liked this article share it with your friends.
    they will thank you later

    Facebook
    Twitter
    Whatsapp

    Copied!